

Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

<https://marketpublishers.com/r/MDBABC528BD4EN.html>

Date: October 2019

Pages: 70

Price: US\$ 1,699.00 (Single User License)

ID: MDBABC528BD4EN

Abstracts

Middle East Respiratory Syndrome (MERS) Drug pipeline report- 2020 is an annual R&D review of Middle East Respiratory Syndrome (MERS) pipeline candidates. The report presents the current status of all major Middle East Respiratory Syndrome (MERS) therapeutic compounds. Detailed insights into Middle East Respiratory Syndrome (MERS) pipeline development, current status, companies, drug profiles and Middle East Respiratory Syndrome (MERS) preclinical and clinical trials are included.

2020 Middle East Respiratory Syndrome (MERS) Pipeline Market Insights
Middle East Respiratory Syndrome (MERS) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Middle East Respiratory Syndrome (MERS) therapies, pipeline by phase and others are included.

Middle East Respiratory Syndrome (MERS) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Middle East Respiratory Syndrome (MERS) Therapeutic Drug candidates
Both active and inactive Middle East Respiratory Syndrome (MERS) pipeline drug candidates are included in the report

Middle East Respiratory Syndrome (MERS) Clinical Trials and preclinical Studies

Middle East Respiratory Syndrome (MERS) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Middle East Respiratory Syndrome (MERS) pipeline market developments
Middle East Respiratory Syndrome (MERS) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Middle East Respiratory Syndrome (MERS) pipeline companies in active development
The report analyzes Middle East Respiratory Syndrome (MERS) pipeline of the below companies-

Autoimmune Technologies LLC, Fabentech, Gilead Sciences Inc, Global BioLife Inc Ltd, Greffex Inc, Humabs BioMed SA, Inovio Pharmaceuticals Inc, Kineta Inc, NanoViricides Inc, Novavax, Inc, Organic Vaccines PLC, Phelix Therapeutics LLC, Planet Biotechnology Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, SAB Biotherapeutics Inc, Signia Therapeutics, Themis Bioscience GmbH, Vaccitech Ltd, Vaxine Pty Ltd, Vir Biotechnology Inc

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

21 Companies investing in Middle East Respiratory Syndrome (MERS) pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Middle East Respiratory Syndrome (MERS) pipeline candidate are included

Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

Contents

1. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE MARKET INSIGHTS, 2020

- 1.1 Middle East Respiratory Syndrome (MERS) Disease Overview
- 1.2 Middle East Respiratory Syndrome (MERS) Drug Pipeline Snapshot, 2020
 - 1.2.1 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Phase
 - 1.2.2 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Company
 - 1.2.3 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Mechanism of Action
 - 1.2.4 Middle East Respiratory Syndrome (MERS) Pipeline Drugs by Route of Administration

2. MIDDLE EAST RESPIRATORY SYNDROME (MERS) COMPANY WISE PIPELINE DETAILS

Autoimmune Technologies LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Fabentech Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Gilead Sciences Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Global BioLife Inc Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Greffex Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Humabs BioMed SA Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Inovio Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Kineta Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

NanoViricides Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Novavax, Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Organic Vaccines PLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Phelix Therapeutics LLC Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Planet Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Regeneron Pharmaceuticals Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Romark Laboratories LC Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

SAB Biotherapeutics Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Signia Therapeutics Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Themis Bioscience GmbH Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Vaccitech Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details

Vaxine Pty Ltd Middle East Respiratory Syndrome (MERS) Pipeline Drugs

Company Profile

Drug Candidate Details
Vir Biotechnology Inc Middle East Respiratory Syndrome (MERS) Pipeline Drugs
Company Profile
Drug Candidate Details

3. MIDDLE EAST RESPIRATORY SYNDROME (MERS) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. MIDDLE EAST RESPIRATORY SYNDROME (MERS) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts

I would like to order

Product name: Middle East Respiratory Syndrome (MERS) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/MDBABC528BD4EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDBABC528BD4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970